Sanuwave Health has announced plans to grow through a non-wound care vertical market, offering its UltraMist product in the aesthetics market.
Sanuwave announced plans for growth through a medical non-wound care vertical market expansion, selling its UltraMist product to the aesthetics market.
Sanuwave will be selling UltraMist, a technology that promotes healing by controlling inflammation and reducing bacteria, for the aesthetics market. It will initially be launched for medspas as a post-facial treatment.
“At Sanuwave, our energy first vision has been focused on sharing clinically effective energy-based products that work to improve patient outcomes and enhance the quality of life,” said Kevin Richardson, chief executive officer and chairman of the board for Sanuwave. “While wound care remains the heart of our business, we have grown to recognize a transferable potential to utilize our energy first ideas and products in parallel ways.”
To ensure steady growth, Sanuwave has strategically engaged with distributors and field experts that will help the company enrich its insight and familiarity within new markets.
“There is a large market opportunity in sports medicine and the Aesthetics industry,” said Richardson. “By partnering with existing players, we have the potential to see a significant upside with little to no upfront capital outlay.”
Sanuwave Health is focused on the research, development, and commercialization of its non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Screenshot via Sanuwave
